The Latest Data on Combining Botox With Anti-CGRP Medications: Heads UP–Episode 68

[fusion_builder_container hundred_percent="yes" overflow="visible" type="legacy" admin_label="post"][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" background_position="left top" background_color="" border_color="" border_style="solid" spacing="yes" background_image="" background_repeat="no-repeat" padding_top="" padding_right="" padding_bottom="" padding_left="" margin_top="0px" margin_bottom="0px" class="" id="" animation_type="" animation_speed="0.3" animation_direction="left" hide_on_mobile="no" center_content="no" min_height="none" align_self="flex-start" border_sizes_undefined="" first="true" last="true" hover_type="none" link="" border_position="all"][fusion_text columns="" column_min_width="" column_spacing="" rule_style="default" rule_size="" rule_color="" content_alignment_medium="" content_alignment_small="" content_alignment="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" class="" id="" font_size="" fusion_font_family_text_font="" fusion_font_variant_text_font="" line_height="" letter_spacing="" text_color="" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset=""][fusion_dropcap color="" boxed="yes" boxed_radius="50%" class="" id=""]T[/fusion_dropcap]here has been much debate about combination therapy with Botox and anti-CGRP monoclonal antibodies including Aimovig, Ajovy, and Emgality. The two medications were not originally studied together leaving physicians uncertain about prescribing practices and many insurance companies unwilling to pay for both treatments. In Episode 68 of Heads UP, Dr. Lindsay Weitzel talks to Dr. Tim Smith about recent data on prescribing these two medications together. What does this mean for our community?[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Previous
Previous

Devices to Treat Migraine Disease and Cluster Headache: Heads UP–Episode 70

Next
Next

New Drug Data Alert – Atogepant: Heads UP–Episode 69